NASDAQ •
Healthcare •
Biotechnology •
Quote as of 09/04/2026 16:00
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization167.83 mln
Float44.41 mln
Earnings Date11/18/2026
Piotroski F-Score
3
/ 9
Below average
Beneish M-Score
10.25
Highly suspicious
Relative Strength
4
/ 100
Severely lagging
Debt / Equity
0.02
Debt-free
Pre-Tax Margin
-2,330%
Severely loss-making
ROE
-145
Deeply negative
Business Description
Founded in 2012 and based in San Diego, California, Connect Biopharma Holdings Limited is working to bring new treatments to patients suffering from conditions where the immune system causes harmful inflammation. Its most advanced drug, rademikibart, blocks a specific protein receptor involved in triggering such reactions and is currently being tested in large-scale clinical trials for atopic dermatitis and asthma.
